Evidence map›Paper›PMID 23773730›Full record

ArticleThe Annals of thoracic surgery2013

Cardiac surgical delivery of the sarcoplasmic reticulum calcium ATPase rescues myocytes in ischemic heart failure.

Anthony S Fargnoli, Michael G Katz, Charles Yarnall, Alice Isidro, Michael Petrov, Nury Steuerwald, Sriparna Ghosh, Kyle C Richardville, Richard Hillesheim, Richard D Williams and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The Annals of thoracic surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. SERCA2a: a key protein in the CaHeart failure reviews · 2020
    Review
  4. Review
  5. Reduced longitudinal contraction is associated with ischemic mitral regurgitation after posterior MI.American journal of physiology. Heart and circulatory physiology · 2018
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Gene therapy to treat cardiac arrhythmias.Nature reviews. Cardiology · 2015
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Anthony S FargnoliSanger Heart & Vascular Institute, Carolinas Healthcare System, Charlotte, North Carolina, USA.
Michael G Katz
Charles Yarnall
Alice Isidro
Michael Petrov
Nury Steuerwald
Sriparna Ghosh
Kyle C Richardville
Richard Hillesheim
Richard D Williams
Erik Kohlbrenner
Hansell H Stedman
Roger J Hajjar
Charles R Bridges
Carolinas Healthcare System · USUniversity of Pennsylvania · US

Funding

Translational Studies in Heart Failure Gene TherapyR01HL083078 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRIDGES, CHARLES R · 2007 to 2018
$9.2M
NHLBI NIH HHS 1-R01 HL083078-01A2NHLBI NIH HHS R01 HL083078
6 · The paper itself

Abstract

backgroundThe sarcoplasmic reticulum calcium ATPase (SERCA2a) is an important molecular regulator of contractile dysfunction in heart failure. Gene transfer of SERCA2a mediated by molecular cardiac surgery with recirculating delivery (MCARD) is a novel and clinically translatable strategy.

methodsIschemic heart failure was induced by ligation of OM1 and OM2 in 14 sheep. Seven sheep underwent MCARD-mediated AAV1-SERCA2a delivery 4 weeks after myocardial infarction, and seven sheep served as untreated controls. Magnetic resonance imaging-based mechanoenergetic studies were performed at baseline, 3 weeks, and 12 weeks after infarction. Myocyte apoptosis was quantified by Tdt-mediated nick-end labeling assay. Myocyte cross-sectional area and caspase-8 and caspase-9 activity was measured with imaging software, specific fluorogenic peptides, and immunohistochemistry.

resultsMCARD-mediated AAV1-SERCA2a gene delivery resulted in robust cardiac-specific SERCA2a expression and stable improvements in global and regional contractility. There were significantly higher stroke volume index, left ventricular fractional thickening, and ejection fraction at 12 weeks in the MCARD group than in the control group (30 ± 3 vs 21 ± 2 mL/m(2); 12% ± 5% vs 3% ± 3%; and 43 ± 4 vs 32 ± 4, respectively, all p < 0.05). Apoptotic myocytes were observed more frequently in the control group than in the MCARD-SERCA2a group (0.57.2 ± 0.16 AU vs 0.32.4 ± 0.08 AU, p < 0.05). MCARD-SERCA2a also resulted in decreased caspase-8 and caspase-9 expression and decreased myocyte area in the border zone of transgenic sheep compared with control sheep (14.6% ± 1.2% vs 2.9% ± 0.7%; 18.2% ± 1.9% vs 8.6% ± 1.4%; and 102.1 ± 3.8 μm(2) vs 88.1 ± 3.6 μm(2), all p < 0.05).

conclusionsMCARD-mediated SERCA2a delivery results in robust cardiac specific gene expression, improved contractility, and a decrease in both myocyte apoptosis and myocyte hypertrophy.

Indexed as

Myocytes, CardiacAnimalsCardiac Surgical ProceduresGenetic TherapyGene Transfer TechniquesHeart FailureSarcoplasmic Reticulum Calcium-Transporting ATPasesSheepSarcoplasmic Reticulum Calcium-Transporting ATPases30

Identifiers

PMID23773730
PMCPMC3735816
OpenAlexW2036400460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.